Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

PIK3CA-Mutated Cancers × inavolisib × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 10 Colorectal Neoplasms 3 Neoplasm Metastasis 2 Triple Negative Breast Neoplasms 1 Solid Tumors 1 PIK3CA-Mutated Cancers 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Metastatic Castration-Resistant Prostate Cancer 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1 inavolisib 1 atezolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06496568 2026-03-18

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers

Hoffmann-La Roche

Phase 1 Recruiting

PIK3CA-Mutated Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡